NEW YORK , March 18, 2023 /PRNewswire/ — Aquavit Holdings has filed an FDA IND for its DTX-024, for the therapy of palmar hyperhidrosis making use of its patented microchannel technologies™. DTKS-024 is a hugely purified and clinically tested injectable neuromodulator derived from the neurotoxin made by Clostridium botulinum.
Akuavit logo (PRNewsfoto/Akuavit Pharmaceuticals, Inc.)
In addition to Aquavit’s biosimilar plan for its botulinum toxin, this will be the world’s initially FDA-authorized solution indicated for palmar hyperhidrosis.
Aquavit is investing in proprietary delivery technologies and associated intellectual house for botulinum toxin. This is a strategic move that puts them ahead of the curve in the rapidly-increasing, multi-billion dollar botulinum toxin market place.
To successfully execute the tactic, Aquavit has lately strengthened its executive group with seasoned veterans from sector and academia.
Dr. David Crean, PhD, MBA, has been appointed Chief Economic Officer of Aquavit Holdings. He has acquire-side and sell-side knowledge in mergers and acquisitions (M&A), partnerships and investments in the life sciences and healthcare sectors, operating inside strategic biopharmaceutical corporations, private equity, investment banking and venture capital. He started his profession in biopharmaceutical corporations more than 30 years ago, notably at Allergan, Abbvie, exactly where he led the execution of acquisitions and sales of technologies, solutions and corporations across a wide variety of therapeutic regions and small business units, which includes injectables. and existing healthcare aesthetics, dermatology, neurology and ophthalmology. He serves on numerous boards, which includes each public and private corporations, and has been honored with a lot of accolades, which includes San Diego’s 500 Most Influential Men and women for the final 4 years (2019 -2022), 2020 Best Believed Leaders by Akial, M&A Advisor of the Year in 2019, and Healthcare Hero 2018
dr. Crean holds FINRA Series 79 and Series 63 licenses and is a registered investment banking representative of BA Securities LLC, member FINRA SIPC.
The story continues
Dr. Churlsu Kwon, MD. dr. MPH., was appointed Chief Health-related Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of knowledge and know-how in scientific improvement, drug improvement and approval, and new drug discovery. He graduated from Oxford University and Harvard Health-related College, and presently holds an academic position at Columbia Health-related College.
With Akuavit’s verified track record in establishing and launching worldwide brands, such as AKUAGOLD®, the firm has demonstrated its capability to effectively bring revolutionary solutions to market place. With its deep know-how of botulinum toxin and in depth doctor network, Aquavit is properly positioned to make a considerable influence in the sector.
“The neurotoxin market place is expanding swiftly, with escalating demand for revolutionary solutions and customized therapy plans.” There is presently no FDA approval for palmar hyperhidrosis and via our new route of administration we will be in a position to offer you new options to meet the increasing desires of individuals. in pathologies that are incredibly debilitating. Offering access to this population is a step in the appropriate path towards enhancing their overall health and properly-getting. ” Churl-Su Kwon, CMO Aquavit.
Aquavit is an revolutionary healthcare firm that supplies a extensive variety of proprietary pharmaceutical, biotechnology and healthcare technologies. Aquavit focuses on customized medicine to increase patient overall health, maximize the efficiency of our healthcare neighborhood and assistance payer pharmacoeconomics.
See original content material for multimedia download: https://vvv.prnevsvire.com/nevs-releases/akuavit-files-extra-ind-for-dtk-024-a-nev-botulinum-tokin-vith-microchannel-technologi-for -palmar-hyperhidrosis-301775589.html
Supply Aquavit Holdings